Six-week data from a 539-patient Phase IIIb trial showed that UCB SA's Cimzia, a PEGylated antitumor-necrosis-factor (TNF)-alpha product, was effective in treating patients with Crohn's disease who are intolerant or no longer responding to infliximab. (BioWorld Today) Read More
